Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Nanostring Technologies Inc's Business Segments
Nanostring Technologies Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 48
Regions Reported
3
Nanostring Technologies Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue Share by Region - FY
- Americas64.8%
- Europe and Middle East22.6%
- Asia Pacific12.6%
Revenue by Geographic Region - FY
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Americas | $ 31 | 64.8% |
| Europe and Middle East | $ 11 | 22.6% |
| Asia Pacific | $ 6 | 12.6% |
Revenue by Product & Service Category - FY
- Product87.1%
- Product, Instruments31%
- Product, Consumables25.2%
- Service8.6%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 42 | 87.1% |
| Product, Instruments | $ 15 | 31% |
| Product, Consumables | $ 12 | 25.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Nanostring Technologies Inc dataset.
Description of Nanostring Technologies Inc
NanoString Technologies Inc.
is a leading diagnostic and biotechnology company that specializes in the development and commercialization of molecular diagnostic tests and genomic research tools.
The company uses a proprietary technology called the nCounter® Analysis System that offers high levels of precision, sensitivity and reproducibility in detecting and quantifying nucleic acids.
The nCounter® Analysis System provides a unique solution to understanding the biology of diseases at a molecular level.
It allows researchers to simultaneously measure the expression levels of hundreds of genes, coding and non-coding RNA species, and copy number variations within a single sample.
This powerful technology doesn’t require any amplification or labeling, making it faster than other methods, while still providing high-resolution data.
NanoString Technologies’ product portfolio includes several diagnostic assays in the areas of clinical oncology, immunology, neurology, and infectious disease.
The company’s flagship product is the Prosigna® Breast Cancer Prognostic Gene Signature Assay, which is FDA-approved for use in postmenopausal women with early-stage breast cancer.
The test helps clinicians to determine which patients may not require chemotherapy after surgery, thereby minimizing the risk of unnecessary treatment.
In addition to its diagnostic assays, NanoString Technologies also provides a range of research tools including the nCounter® Analysis System, gene expression panels and assays, protein array products, and digital spatial profiling platform for spatially resolved tissue analysis.
NanoString Technologies have exclusive collaborations with major pharmaceutical companies such as Merck, Pfizer, and Biogen, who use the company’s technology to develop new therapeutics and clinical biomarkers.
NanoString Technologies went public in 2013, and currently has its headquarters in Seattle, Washington.
The company has several offices worldwide, including in Europe and Asia-Pacific.
It continues to lead innovation in the genomics industry with its state-of-the-art technology and diagnostic solutions.
is a leading diagnostic and biotechnology company that specializes in the development and commercialization of molecular diagnostic tests and genomic research tools.
The company uses a proprietary technology called the nCounter® Analysis System that offers high levels of precision, sensitivity and reproducibility in detecting and quantifying nucleic acids.
The nCounter® Analysis System provides a unique solution to understanding the biology of diseases at a molecular level.
It allows researchers to simultaneously measure the expression levels of hundreds of genes, coding and non-coding RNA species, and copy number variations within a single sample.
This powerful technology doesn’t require any amplification or labeling, making it faster than other methods, while still providing high-resolution data.
NanoString Technologies’ product portfolio includes several diagnostic assays in the areas of clinical oncology, immunology, neurology, and infectious disease.
The company’s flagship product is the Prosigna® Breast Cancer Prognostic Gene Signature Assay, which is FDA-approved for use in postmenopausal women with early-stage breast cancer.
The test helps clinicians to determine which patients may not require chemotherapy after surgery, thereby minimizing the risk of unnecessary treatment.
In addition to its diagnostic assays, NanoString Technologies also provides a range of research tools including the nCounter® Analysis System, gene expression panels and assays, protein array products, and digital spatial profiling platform for spatially resolved tissue analysis.
NanoString Technologies have exclusive collaborations with major pharmaceutical companies such as Merck, Pfizer, and Biogen, who use the company’s technology to develop new therapeutics and clinical biomarkers.
NanoString Technologies went public in 2013, and currently has its headquarters in Seattle, Washington.
The company has several offices worldwide, including in Europe and Asia-Pacific.
It continues to lead innovation in the genomics industry with its state-of-the-art technology and diagnostic solutions.
Nanostring Technologies Inc. is a leading biotechnology company focused on developing advanced molecular profiling technologies to support improved diagnosis, treatment, and understanding of various diseases. The firm is dedicated to providing cutting-edge solutions that cater to the diverse and evolving needs of researchers and clinicians in molecular biology, genomics, and personalized medicine.
Segments
Nanostring Technologies operates primarily through two distinct segments: Products and Services.
1) Products
Nanostring offers a robust portfolio of innovative products designed to facilitate biomarker discovery, molecular profiling, and gene expression analysis. The product lineup includes:
a) nCounter Analysis System:
A hallmark of Nanostrings offerings, the nCounter Analysis System uses digital barcoding technology to quantify gene expression levels from various biological samples. This system enables the simultaneous analysis of up to 800 genes, providing high sensitivity and precision. It is widely used in research settings, including cancer research, immunology, and neurological diseases.
b) GeoMx Digital Spatial Profiler (DSP):
The GeoMx DSP is a sophisticated platform that allows for high-throughput spatial gene expression analysis within tissue samples. The technology offers researchers the capability to visualize the spatial distribution of RNA and proteins in a tissue context, which is crucial for understanding cellular interactions and heterogeneity in the tumor microenvironment.
c) Prosigna Breast Cancer Test:
This FDA-cleared diagnostic test leverages gene expression profiling to classify breast cancer into intrinsic biological subtypes, allowing oncologists to make informed decisions about patient management. It provides critical information regarding the likelihood of cancer recurrence, thus aiding in treatment personalization.
d) Visium Spatial Gene Expression Solution:
The Visium solution combines histological imaging with transcriptomic analysis. Researchers can obtain high-resolution spatial gene expression data within intact tissue samples, thereby gaining insights into tissue architecture and cellular organization.
2) Services
Nanostring Technologies also provides a comprehensive suite of services aimed at supporting various genomic research applications, ensuring clients have access to expert assistance throughout their projects. Some key services include:
a) nCounter Dx Analysis System Services:
This service facilitates the high-resolution analysis of gene expression and copy number variations in clinical specimens, helping clinicians to tailor treatments based on the molecular characterizations of individual tumors.
b) Prosigna Breast Cancer Assay Diagnostic Services:
In addition to product sales, the company offers diagnostic services utilizing the Prosigna test, which includes extensive gene expression profiling to assess breast cancer recurrence risks and guide therapeutic decisions.
c) Custom Gene Expression Profiling:
Researchers can engage in custom assay services tailored to their specific scientific questions, providing flexibility to investigate gene expression in unique experimental contexts.
Products and Services
Nanostring Technologies provides a comprehensive array of products and services that serve diverse research applications across various life sciences fields:
1) Gene Expression Analysis:
Nanostring’s platforms, such as the nCounter, GeoMx DSP, and Visium, empower researchers to conduct intricate studies on gene expression patterns across a range of biological systems. These enable significant advancements in biomarker discovery, therapeutic target identification, and understanding disease mechanisms.
2) Diagnostics:
The diagnostic tools offered, such as the Prosigna Test and nCounter Dx Analysis System, enhance the clinical landscape by equipping healthcare professionals with accurate molecular insights, facilitating better treatment planning and patient management.
3) Sequencing Services:
Through its services, Nanostring provides comprehensive support in sample preparation and sequencing, alongside robust data analysis capabilities, enabling researchers to obtain high-quality genomic data efficiently.
4) Custom Genotyping:
Offering tailored genotyping services allows researchers to design specific assays to explore genetic variants pertinent to their hypotheses, providing them with unprecedented flexibility in experimental design.
Conclusion
Overall, Nanostring Technologies Inc. stands at the forefront of biotechnology innovation, with its diverse range of products and services designed to meet the multi-faceted needs of researchers and clinicians across oncology, immunology, neuroscience, and genomics. Their commitment to advancing molecular profiling technologies has significant implications for understanding diseases, guiding treatment decisions, and enhancing patient outcomes.
Segments
Nanostring Technologies operates primarily through two distinct segments: Products and Services.
1) Products
Nanostring offers a robust portfolio of innovative products designed to facilitate biomarker discovery, molecular profiling, and gene expression analysis. The product lineup includes:
a) nCounter Analysis System:
A hallmark of Nanostrings offerings, the nCounter Analysis System uses digital barcoding technology to quantify gene expression levels from various biological samples. This system enables the simultaneous analysis of up to 800 genes, providing high sensitivity and precision. It is widely used in research settings, including cancer research, immunology, and neurological diseases.
b) GeoMx Digital Spatial Profiler (DSP):
The GeoMx DSP is a sophisticated platform that allows for high-throughput spatial gene expression analysis within tissue samples. The technology offers researchers the capability to visualize the spatial distribution of RNA and proteins in a tissue context, which is crucial for understanding cellular interactions and heterogeneity in the tumor microenvironment.
c) Prosigna Breast Cancer Test:
This FDA-cleared diagnostic test leverages gene expression profiling to classify breast cancer into intrinsic biological subtypes, allowing oncologists to make informed decisions about patient management. It provides critical information regarding the likelihood of cancer recurrence, thus aiding in treatment personalization.
d) Visium Spatial Gene Expression Solution:
The Visium solution combines histological imaging with transcriptomic analysis. Researchers can obtain high-resolution spatial gene expression data within intact tissue samples, thereby gaining insights into tissue architecture and cellular organization.
2) Services
Nanostring Technologies also provides a comprehensive suite of services aimed at supporting various genomic research applications, ensuring clients have access to expert assistance throughout their projects. Some key services include:
a) nCounter Dx Analysis System Services:
This service facilitates the high-resolution analysis of gene expression and copy number variations in clinical specimens, helping clinicians to tailor treatments based on the molecular characterizations of individual tumors.
b) Prosigna Breast Cancer Assay Diagnostic Services:
In addition to product sales, the company offers diagnostic services utilizing the Prosigna test, which includes extensive gene expression profiling to assess breast cancer recurrence risks and guide therapeutic decisions.
c) Custom Gene Expression Profiling:
Researchers can engage in custom assay services tailored to their specific scientific questions, providing flexibility to investigate gene expression in unique experimental contexts.
Products and Services
Nanostring Technologies provides a comprehensive array of products and services that serve diverse research applications across various life sciences fields:
1) Gene Expression Analysis:
Nanostring’s platforms, such as the nCounter, GeoMx DSP, and Visium, empower researchers to conduct intricate studies on gene expression patterns across a range of biological systems. These enable significant advancements in biomarker discovery, therapeutic target identification, and understanding disease mechanisms.
2) Diagnostics:
The diagnostic tools offered, such as the Prosigna Test and nCounter Dx Analysis System, enhance the clinical landscape by equipping healthcare professionals with accurate molecular insights, facilitating better treatment planning and patient management.
3) Sequencing Services:
Through its services, Nanostring provides comprehensive support in sample preparation and sequencing, alongside robust data analysis capabilities, enabling researchers to obtain high-quality genomic data efficiently.
4) Custom Genotyping:
Offering tailored genotyping services allows researchers to design specific assays to explore genetic variants pertinent to their hypotheses, providing them with unprecedented flexibility in experimental design.
Conclusion
Overall, Nanostring Technologies Inc. stands at the forefront of biotechnology innovation, with its diverse range of products and services designed to meet the multi-faceted needs of researchers and clinicians across oncology, immunology, neuroscience, and genomics. Their commitment to advancing molecular profiling technologies has significant implications for understanding diseases, guiding treatment decisions, and enhancing patient outcomes.